FibroBiologics, Inc.

FBLG

US31573L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
4.93 ^USD	+16.55%		-1.20%	0.00%

Jul. 01	FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Small Cap Completeness Index	CI
Jul. 01	FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Microcap Growth Index	CI

FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2500 Index

July 30, 2024

Latest news about FibroBiologics, Inc.

FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Small Cap Completeness Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Microcap Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2000 Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 3000E Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Microcap Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2500 Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 3000E Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 3000 Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2000 Growth Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2000 Dynamic Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 2500 Index	Jun. 30	CI
FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell 3000 Index	Jun. 30	CI
Fibrobiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology	Jun. 25	CI
FibroBiologics to Join Russell 2000 Index in July	Jun. 13	MT
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	Apr. 25	CI
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA	Apr. 04	CI
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel	Mar. 06	CI
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Top Premarket Gainers	Feb. 28	MT
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	Feb. 20	CI
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases	Feb. 13	CI
Top Premarket Gainers	Feb. 01	MT

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Annual General Meeting

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FIBROBIOLOGICS, INC.	0.00%	161M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs